Literature DB >> 27311561

Adherence to Antiretroviral Therapy and Tuberculosis Treatment in a Prison of Tehran, Iran.

Seyed Ahmad Seyed Alinaghi, Behnam Farhoudi1, Minoo Mohraz, Amin Alipour, Raheleh Golrokhy, Mostafa Hosseini, Jamal Miri.   

Abstract

BACKGROUND: The human immune system can be impaired due to lack of adherence to treatment among HIV positive patients. This is reflected in lower levels of CD4 count and incomplete viral suppression leading to the disease's progression and increased risks of opportunistic infections. Little is known about adherence to antiretroviral therapy (ART) and Tuberculosis (TB) treatment and barriers to ART adherence faced by prisoners. Therefore, we conducted a study to evaluate adherence to ART, treatment of latent TB infection (LTBI), and TB treatment and barriers of ART adherence in the Great Tehran Prison in 2014.
MATERIALS AND METHODS: We conducted a study to evaluate adherence to ART, latent TB infection treatment, and TB treatment via Directly Observed Therapy (DOT) among HIV positive patients in the Great Tehran Prison in 2014. Furthermore, we examined the barriers of adherence to ART through focus group discussions (FGDs) with 22 people living with HIV in the prison.
RESULTS: The mean of adherence to ART, latent TB infection treatment, and TB treatment were 93.3%, 92.7% and 93.3%, respectively. Addiction, negative drug reactions, bad experiences with staffs, and psychosocial and nutritional problems were cited as the most common barriers to adherence.
CONCLUSION: It is recommended to implement DOT for ART in Iranian prisons. In addition, through removing the barriers and implementation of DOT for ART, HIV positive prisoners can achieve a complete adherence.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27311561     DOI: 10.2174/1871526516666160616111308

Source DB:  PubMed          Journal:  Infect Disord Drug Targets        ISSN: 1871-5265


  7 in total

1.  Drug resistance patterns in HIV patients with virologic failure in Iran.

Authors:  Seyed Ahmad Seyed Alinaghi; Mehrnaz Rasoolinejad; Zeinab Najafi; Omid Dadras; Ehsan Malekianzadeh; Ali Mirzazadeh
Journal:  Arch Clin Infect Dis       Date:  2019-12-28

2.  A systematic review and meta-analyses on initiation, adherence and outcomes of antiretroviral therapy in incarcerated people.

Authors:  Terefe G Fuge; George Tsourtos; Emma R Miller
Journal:  PLoS One       Date:  2020-05-18       Impact factor: 3.240

3.  Factors affecting optimal adherence to antiretroviral therapy and viral suppression amongst HIV-infected prisoners in South Ethiopia: a comparative cross-sectional study.

Authors:  Terefe Gone Fuge; George Tsourtos; Emma R Miller
Journal:  AIDS Res Ther       Date:  2022-01-29       Impact factor: 2.250

4.  'You just prefer to die early!': how socioecological context impedes treatment for people living with HIV in Iran.

Authors:  Vira Ameli; Leila Taj; Jane Barlow; Lora Sabin; Franziska Meinck; Jessica Haberer; Minoo Mohraz
Journal:  BMJ Glob Health       Date:  2021-11

5.  The role of online social networks in improving health literacy and medication adherence among people living with HIV/AIDS in Iran: Development of a conceptual model.

Authors:  Azam Bazrafshani; Sirous Panahi; Hamid Sharifi; Effat Merghati-Khoei
Journal:  PLoS One       Date:  2022-06-30       Impact factor: 3.752

Review 6.  HIV Prevalence and Correlations in Prisons in Different Regions of the World: A Review Article.

Authors:  Raheleh Golrokhi; Behnam Farhoudi; Leila Taj; Fatemeh Golsoorat Pahlaviani; Elham Mazaheri-Tehrani; Andrea Cossarizza; SeyedAhmad SeyedAlinaghi; Minoo Mohraz; Fabrício Azevedo Voltarelli
Journal:  Open AIDS J       Date:  2018-08-31

7.  A simple risk-based strategy for hepatitis C virus screening among incarcerated people in a low- to middle-income setting.

Authors:  Sanam Hariri; Maryam Sharafkhah; Maryam Alavi; Gholamreza Roshandel; Abdolreza Fazel; Taghi Amiriani; Nazgol Motamed-Gorji; Abolfazl Bazazan; Shahin Merat; Hossein Poustchi; Reza Malekzadeh
Journal:  Harm Reduct J       Date:  2020-08-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.